This protocol addresses adults with acute myeloid leukaemia classified as ELN favourable or intermediate risk who have achieved complete remission (CR) or CR with incomplete haematological recovery (CRi) following a second induction cycle — and who do not have core binding factor AML, therapy-related AML, AML with myelodysplasia-related changes, FLT3-ITD/TKD-positive disease, or ELN adverse-risk features.
ELN favourable or intermediate risk AML, specifically excluding: core binding factor AML, therapy-related AML, AML with myelodysplasia-related changes, FLT3-ITD/TKD-positive disease, and ELN adverse-risk classification. In patients where none of these markers is present, standard induction chemotherapy is the initial approach.
The prior step was a second induction cycle — either repeating the initial induction regimen or a regimen incorporating intermediate-dose cytarabine (IDAC), such as FLAG-Ida. The aim was to achieve CR/CRi (fewer than 5% blasts in the bone marrow). Having reached that remission milestone, this consolidation protocol defines the next phase of management.
Post-remission management for these patients involves either chemotherapy consolidation or haematopoietic cell transplantation. The appropriate pathway differs by ELN risk group and by individual patient factors. The complete algorithm — including risk-stratified sequencing and eligibility considerations — is in the full protocol.